Under EU orphan drug legislation, newly authorized medicines for rare diseases are eligible for a decade of protection from market competitors – a rule that offers an important financial incentive for pharmaceutical companies to develop therapies for niche indications.
The enforcement of this incentive, as set out under Article 8(1) of the EU Regulation on Orphan Medicinal Products, has traditionally fallen on the regulator, under public law
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?